1. Combination therapy for multidrug-resistant cytomegalovirus disease
- Author
-
Alexis Dumoulin, Nina Khanna, Christian P. Kalberer, Alicia Rovó, Manuel Battegay, Jan Dirks, Jörg Halter, A. Schibli, Claudia Stuehler, Dominik Heim, Hans H. Hirsch, Jacob Passweg, Maja Weisser, Justyna Nowakowska, Christoph Bucher, and Georg Stussi
- Subjects
Ganciclovir ,Foscarnet ,Male ,Combination therapy ,medicine.medical_treatment ,Congenital cytomegalovirus infection ,Hematopoietic stem cell transplantation ,Antiviral Agents ,chemistry.chemical_compound ,Immunocompromised Host ,Drug Resistance, Multiple, Viral ,medicine ,Humans ,Transplantation ,business.industry ,Hematopoietic Stem Cell Transplantation ,virus diseases ,Maribavir ,Middle Aged ,medicine.disease ,Adoptive Transfer ,Combined Modality Therapy ,Multiple drug resistance ,surgical procedures, operative ,Infectious Diseases ,chemistry ,Immunology ,Cytomegalovirus Infections ,Drug Therapy, Combination ,business ,medicine.drug ,Cidofovir - Abstract
Multidrug-resistant (MDR) cytomegalovirus (CMV) emerged after transient responses to ganciclovir, foscarnet, and cidofovir in a CMV-seropositive recipient who underwent allogeneic hematopoietic stem cell transplantation from a CMV-seronegative donor. Experimental treatments using leflunomide and artesunate failed. Re-transplantation from a CMV-seropositive donor supported by adoptive transfer of pp65-specific T cells and maribavir was followed by lasting suppression. This case illustrates that successful MDR CMV therapy may require individualized multidisciplinary approaches.
- Published
- 2015